Scholarlink

Introduction <p>For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients.</p> Areas Covered <p>This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real-world practice are provided.</p> Expert Opinion <p>In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月6日

查看全文
  • Miquel Bernardo,
  • Marina Díaz Marsá,
  • Ana González-Pinto,
  • Manuel Martín Carrasco,
  • Víctor Pérez Sola,
  • Pilar Alejandra Sáiz,
  • Eduard Vieta,
  • Marta Torrens,
  • Celso Arango,
  • Benedicto Crespo-Facorro

摘要

Introduction

For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychotic-naïve and previously treated patients.

Areas Covered

This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real-world practice are provided.

Expert Opinion

In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.